Analyzing Recent Options Activity for Biogen (NASDAQ: BIIB)
Jan 21, 2025
Biogen Equities
Biogen (BIIB) Faces Downtrend, But a Turnaround May Be Imminent
Nov 5, 2024
Biogen Reports Positive Outcomes from Higher-Dose Nusinersen Trial in SMA Treatment
Sep 5, 2024
Biogen Announces European Approval for Tocilizumab Biosimilar, TOFIDENCE™
Jun 25, 2024
FDA Approves Eisai's LEQEMBI® Maintenance Dosing Application for Early Alzheimer's Treatment
Jun 10, 2024
European Commission Revokes Marketing Authorizations for Generic TECFIDERA® Variants; Biogen Affected
Dec 20, 2023